{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:27:47Z","timestamp":1791613667341,"version":"4.3.4"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Multiple myeloma (MM) is a malignant disease of plasma cells that accounts for approximately 10% of all hematological malignancies and is characterized by a clonal proliferation of malignant plasma cells in the bone marrow. Numerous therapeutic strategies, including proteasome inhibitors, immunomodulators, monoclonal antibodies against CD38 and autologous stem cell transplantation, have prolonged the median survival of MM patients. Nevertheless, almost all MM patients suffer disease relapses due to drug resistance and eventually die from MM or MM-related complications. Chimeric antigen receptor (CAR) T-cell therapy is a novel immunotherapy strategy for MM and has shown encouraging results in several clinical trials. However, the use of CAR T-cell therapy for the treatment of MM is still associated with several difficulties, including antigen escape, poor persistence, an immunosuppressive microenvironment, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, CAR T-cell-associated encephalopathy syndrome, cytopenia, and infections. In this review, we describe in detail the target antigens of CAR T cells in MM. We also comprehensively discuss recent innovations in the development of CAR T cells to improve clinical efficacy and strategies to overcome the limitations of CAR T-cell therapy in MM.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1499590","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T07:22:41Z","timestamp":1740554561000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["CAR\u2010T cells in the treatment of multiple myeloma: an encouraging cell therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Tong","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hang","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Fei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig","year":"2015","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12185-020-02829-6","article-title":"Molecular basis of clonal evolution in multiple myeloma","volume":"111","author":"Furukawa","year":"2020","journal-title":"Int J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2217\/rme-2020-0033","article-title":"Industry updates from the field of stem cell research and regenerative medicine in February 2020","volume":"15","author":"Ilic","year":"2020","journal-title":"Regenerative Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Jesus","year":"2021","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.10.012","article-title":"Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma","volume":"29","author":"Zhou","year":"2023","journal-title":"J Infect Chemother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.2019.8.issue-5","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Trans Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.3390\/jcm11082158","article-title":"Development of CAR T cell therapy in children\u2013A comprehensive overview","volume":"11","author":"Boettcher","year":"2022","journal-title":"J Clin Med."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.v14.6","article-title":"Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions","volume":"14","author":"Curran","year":"2012","journal-title":"J Gene Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/cancers10090323","article-title":"CAR-T cells based on novel BCMA monoclonal antibody block multiple myeloma cell growth","volume":"10","author":"Berahovich","year":"2018","journal-title":"Cancers."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280629","article-title":"A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed\/refractory multiple myeloma: results from phase I clinical trials","volume":"107","author":"Yang","year":"2022","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","first-page":"115691","DOI":"10.1016\/j.biopha.2023.115691","article-title":"Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma","volume":"168","author":"Yuti","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290012146","article-title":"CD19 expression and growth inhibition of tumours in human multiple myeloma","volume":"43","author":"Ishikawa","year":"2002","journal-title":"Leukemia lymphoma"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: a (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leukemia Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/BF01697400","article-title":"Multiparameter analyses of normal and Malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells","volume":"64","author":"Leo","year":"1992","journal-title":"Ann Hematology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: A target for immunotherapeutic approaches in multiple myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21771","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.623257","article-title":"Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression","volume":"53","author":"Tembhare","year":"2012","journal-title":"Leukemia lymphoma"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3023","article-title":"CD44: can a cancer-initiating cell profit from an abundantly expressed molecule","volume":"11","author":"Z\u00f6ller","year":"2011","journal-title":"Nat Rev Cancer."},{"key":"B36","article-title":"CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q","volume":"90","author":"Liebisch","year":"2005","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761643","article-title":"CD138 mediates selection of mature plasma cells by regulating their survival","volume":"129","author":"McCarron","year":"2017","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cell Immunother"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"New Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"JCO2401785","DOI":"10.1200\/JCO-24-01785","article-title":"Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: an updated analysis","volume":"2024","author":"Jurgens","year":"2024","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting Malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia","volume":"18","author":"Polson","year":"2006","journal-title":"Int Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor\u2013redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-020-00113-y","article-title":"Multiple myeloma and integrins","volume":"61","author":"Hosen","year":"2020","journal-title":"[Rinsho ketsueki] Japanese J Clin hematology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-021-03162-2","article-title":"Expression of activated integrin \u03b27 in multiple myeloma patients","volume":"114","author":"Hosen","year":"2021","journal-title":"Int J Hematology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4431","article-title":"The activated conformation of integrin \u03b27 is a novel multiple myeloma\u2013specific target for CAR T cell therapy","volume":"23","author":"Hosen","year":"2017","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2010.174","article-title":"Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells","volume":"18","author":"Barber","year":"2011","journal-title":"Gene Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902000","article-title":"Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment","volume":"183","author":"Barber","year":"2009","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2008.04.010","article-title":"Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma","volume":"36","author":"Barber","year":"2008","journal-title":"Exp hematology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2020-142695","article-title":"Phase 1\/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies","volume":"136","author":"Costello","year":"2020","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: final results of a phase I clinical trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1182\/blood-2019-126689","article-title":"Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting APRIL for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Popat","year":"2019","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.662169","article-title":"Case report: multiple vertebral compression fractures in 14-year-old children with multiple myeloma","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"103873","DOI":"10.1016\/j.ebiom.2022.103873","article-title":"CAR-macrophage: An extensive immune enhancer to fight cancer","volume":"76","author":"Wang","year":"2022","journal-title":"EBioMedicine"},{"key":"B67","doi-asserted-by":"publisher","first-page":"111128","DOI":"10.1016\/j.celrep.2022.111128","article-title":"Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy","volume":"40","author":"Chang","year":"2022","journal-title":"Cell Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: State of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci Adv"},{"key":"B69","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1038\/s41467-021-25605-4","article-title":"Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens","volume":"12","author":"Hwang","year":"2021","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s12254-020-00571-7","article-title":"CAR-T cells in multiple myeloma: current status","volume":"13","author":"Steiner","year":"2020","journal-title":"memo - Magazine Eur Med Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"[amp]]gamma;-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"B73","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J immunotherapy Cancer"},{"key":"B78","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther oncolytics"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer discovery"},{"key":"B80","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092513","article-title":"The leading role of the immune microenvironment in multiple myeloma: A new target with a great prognostic and clinical value","volume":"11","author":"Desantis","year":"2022","journal-title":"J Clin Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040988","article-title":"Challenges for immunotherapy in multiple myeloma: bone marrow microenvironment-mediated immune suppression and immune resistance","volume":"12","author":"Holthof","year":"2020","journal-title":"Cancers"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/nature19364","article-title":"Ionic immune suppression within the tumour microenvironment limits T cell effector function","volume":"537","author":"Eil","year":"2016","journal-title":"Nature"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer discovery"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B87","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat Commun"},{"key":"B88","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40364-020-00192-6","article-title":"Characterization of novel dual tandem CD19\/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma","volume":"8","author":"Kang","year":"2020","journal-title":"biomark Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018598","article-title":"Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma","volume":"141","author":"Roddie","year":"2023","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells11213386","article-title":"Modification of hinge\/transmembrane and signal transduction domains improves the expression and signaling threshold of GXMR-CAR specific to cryptococcus spp","volume":"11","author":"Dos Santos","year":"2022","journal-title":"Cells"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092523","article-title":"Bispecific chimeric antigen receptor T cell therapy for B cell Malignancies and multiple myeloma","volume":"12","author":"Cronk","year":"2020","journal-title":"Cancers"},{"key":"B92","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1182\/blood-2019-131056","article-title":"A bcma and CD19 bispecific CAR-T for relapsed and refractory multiple myeloma","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J Clin Invest"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunology Immunother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"B99","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"key":"B100","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nrclinonc.2016.65","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1499590\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T07:22:45Z","timestamp":1740554565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1499590\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":100,"alternative-id":["10.3389\/fimmu.2025.1499590"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1499590","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"article-number":"1499590"}}